Table of Contents

This article has been retracted as it is found to contain a substantial amount of material from the paper "Hypofractionation for Prostate Cancer: A Critical Review," Edward F. Miles, W. Robert Lee, Seminars in Radiation Oncology - January 2008 (Vol. 18, Issue 1, Pages 41-47, DOI: 10.1016/j.semradonc.2007.09.006).

ISRN Oncology
Volume 2012 (2012), Article ID 410892, 5 pages
Review Article

Review of Hypofractionated Radiotherapy for Prostate Cancer

Department of Radiation Oncology and Stereotactic Radiotherapy, Medical School, University of Patras, 26504 Patras, Greece

Received 16 April 2012; Accepted 15 June 2012

Academic Editors: A. E. Bilsland and O. Hansen

Copyright © 2012 Despina Spyropoulou and Dimitrios Kardamakis. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Hypofractionated radiotherapy for prostate cancer has become of increasing interest with the recognition of a potential improvement in therapeutic outcome with treatments delivered in large-sized daily fractions. In addition, hypofractionation offers a reduction in fraction number and produces attractive cost and increased convenience for patients. There is convincing evidence, by several clinical trials, that biochemical control is significantly improved with higher administered radiation doses to the prostate gland. Furthermore, the improved radiation delivery techniques such as 3D conformal radiotherapy (3DCRT) or, better, intensity modulated radiation therapy (IMRT) allow high administered doses to the prostate while sparing the normal surrounding tissues. Several studies of the radiobiology of prostate cancer suggest that it may be more susceptible to large fraction sizes compared with conventional fractionation of external beam radiation.